CD4 and neoplasm: The consequence of MHCII upregulation on tumor cells is two-fold, which not only benefited the CD4+ T-cell-meditated targeting of tumor cells, but also facilitated the programming of CD4+ T cells with enhanced polyfunctionality and memory potential.